This study cohort included 15 CK-AML patients with wild-type TP53, a male/female ratio of 1.14 (8∶7) and median age of 59 years (range, 17–80 years), with seven patients (46.7%) ≥60 years. Here, TP53 is linked to acute myeloid leukemia.